UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $24.36 Million Stock Holdings in Inspire Medical Systems, Inc. $INSP

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 21.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 546,020 shares of the company’s stock after acquiring an additional 97,233 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.89% of Inspire Medical Systems worth $24,358,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Inspire Medical Systems in the second quarter worth about $211,341,000. Wellington Management Group LLP acquired a new stake in Inspire Medical Systems during the fourth quarter valued at approximately $203,929,000. Deerfield Management Company L.P. grew its stake in shares of Inspire Medical Systems by 648.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after purchasing an additional 907,694 shares during the period. Morgan Stanley grew its stake in shares of Inspire Medical Systems by 179.5% in the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after purchasing an additional 809,121 shares during the period. Finally, Fuller & Thaler Asset Management Inc. acquired a new position in shares of Inspire Medical Systems in the 4th quarter worth approximately $61,619,000. Institutional investors own 94.91% of the company’s stock.

Insiders Place Their Bets

In other Inspire Medical Systems news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on INSP. Truist Financial reaffirmed a “hold” rating and issued a $62.00 price target (up from $54.00) on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Weiss Ratings upgraded Inspire Medical Systems from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, August 19th. Zacks Research raised Inspire Medical Systems from a “hold” rating to a “strong-buy” rating in a report on Monday, August 17th. Bank of America lowered shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price on the stock. in a report on Friday, May 22nd. Finally, Mizuho increased their target price on shares of Inspire Medical Systems from $55.00 to $65.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $66.19.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $62.99 on Friday. Inspire Medical Systems, Inc. has a 52 week low of $38.91 and a 52 week high of $147.03. The stock has a market capitalization of $1.82 billion, a PE ratio of 13.63, a PEG ratio of 4.72 and a beta of 0.70. The stock’s fifty day moving average is $55.05 and its 200-day moving average is $52.43.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.38. The business had revenue of $200.58 million for the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm’s quarterly revenue was down 7.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, analysts forecast that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.